BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21409347)

  • 1. Evaluation of outcome prediction and disease extension by quantitative 2-deoxy-2-[18F] fluoro-D-glucose with positron emission tomography in patients with small cell lung cancer.
    Arslan N; Tuncel M; Kuzhan O; Alagoz E; Budakoglu B; Ozet A; Ozguven MA
    Ann Nucl Med; 2011 Jul; 25(6):406-13. PubMed ID: 21409347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
    Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
    Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
    Zhu D; Ma T; Niu Z; Zheng J; Han A; Zhao S; Yu J
    Lung Cancer; 2011 Sep; 73(3):332-7. PubMed ID: 21292341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of total lesion glycolysis by 18F-FDG PET/CT in surgically resected stage IA non-small cell lung cancer.
    Park SY; Cho A; Yu WS; Lee CY; Lee JG; Kim DJ; Chung KY
    J Nucl Med; 2015 Jan; 56(1):45-9. PubMed ID: 25525185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
    Kahraman D; Scheffler M; Zander T; Nogova L; Lammertsma AA; Boellaard R; Neumaier B; Ullrich RT; Holstein A; Dietlein M; Wolf J; Kobe C
    J Nucl Med; 2011 Dec; 52(12):1871-7. PubMed ID: 22065872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body metabolic tumour volume of 18F-FDG PET/CT improves the prediction of prognosis in small cell lung cancer.
    Oh JR; Seo JH; Chong A; Min JJ; Song HC; Kim YC; Bom HS
    Eur J Nucl Med Mol Imaging; 2012 Jun; 39(6):925-35. PubMed ID: 22270509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of simultaneously acquired diffusion-weighted imaging and 2-deoxy-[18F] fluoro-2-D-glucose positron emission tomography of pulmonary lesions in a dedicated whole-body magnetic resonance/positron emission tomography system.
    Schmidt H; Brendle C; Schraml C; Martirosian P; Bezrukov I; Hetzel J; Müller M; Sauter A; Claussen CD; Pfannenberg C; Schwenzer NF
    Invest Radiol; 2013 May; 48(5):247-55. PubMed ID: 23519008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer.
    Lee YJ; Cho A; Cho BC; Yun M; Kim SK; Chang J; Moon JW; Park IK; Choi HJ; Kim JH
    Clin Cancer Res; 2009 Apr; 15(7):2426-32. PubMed ID: 19318478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of integrated 18F-FDG PET-CT as a staging tool for limited-stage small cell lung cancer: a retrospective study.
    Sohn BS; Lee DH; Kim EK; Yoon DH; Kim HO; Ryu JS; Kim SW; Suh C
    Onkologie; 2012; 35(7-8):432-8. PubMed ID: 22846975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
    Heusch P; Buchbender C; Köhler J; Nensa F; Gauler T; Gomez B; Reis H; Stamatis G; Kühl H; Hartung V; Heusner TA
    J Nucl Med; 2014 Mar; 55(3):373-8. PubMed ID: 24504054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
    Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
    Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of metabolic parameters on baseline 18F-FDG PET/CT in small cell lung cancer.
    Araz M; Soydal C; Özkan E; Sen E; Nak D; Kucuk ON; Gönüllü U; Kir KM
    Q J Nucl Med Mol Imaging; 2022 Mar; 66(1):61-66. PubMed ID: 31271268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of FDG PET/CT in Patients with Pancoast Tumors: Does It Add Any Contribution to Patient Management?
    Ozmen O; Yilmaz U; Dadali Y; Tatci E; Gokcek A; Aydin E; Okuyucu K; Arslan N
    Cancer Biother Radiopharm; 2015 Oct; 30(8):359-67. PubMed ID: 26367245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG uptake as a biologic factor predicting outcome in patients with resected non-small-cell lung cancer.
    Zhang ZJ; Chen JH; Meng L; Du JJ; Zhang L; Liu Y; Dai HH
    Chin Med J (Engl); 2007 Jan; 120(2):125-31. PubMed ID: 17335654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) uptake measured by positron emission tomography is associated with reduced overall survival in patients with oral squamous cell carcinoma.
    Hofele C; Freier K; Thiele OC; Haberkorn U; Buchmann I
    Oral Oncol; 2009 Nov; 45(11):963-7. PubMed ID: 19665923
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic value of the quantitative metabolic volumetric measurement on 18F-FDG PET/CT in Stage IV nonsurgical small-cell lung cancer.
    Liao S; Penney BC; Zhang H; Suzuki K; Pu Y
    Acad Radiol; 2012 Jan; 19(1):69-77. PubMed ID: 22142679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer: tumor SUVmean has superior prognostic value.
    Higgins KA; Hoang JK; Roach MC; Chino J; Yoo DS; Turkington TG; Brizel DM
    Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):548-53. PubMed ID: 21277108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The application of 18F-fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer].
    Xu HF; Liu Y; Zhang JH; Zhou RS; Zhou FH; Yuan MH
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 Feb; 28(2):108-11. PubMed ID: 15854393
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of
    Lee JW; Choi JS; Lyu J; Lee SM
    Lung Cancer; 2018 Apr; 118():41-47. PubMed ID: 29572001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.